Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy. Williams N, Silva F, Schmolke M. Antiviral Res 2024 Jun 28:105951. doi: 10.1016/j.antiviral.2024.105951.

Read + Share

Amedeo Smart

Independent Medical Education

Williams N, Silva F, Schmolke M. Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy. Antiviral Res 2024 Jun 28:105951. doi: 10.1016/j.antiviral.2024.105951.
PMID: 38945485